skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: American Society of Hematology remover assunto: Multiple Myeloma - Drug Therapy remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Avet-Loiseau, Hervé ; Fonseca, Rafael ; Siegel, David ; Dimopoulos, Meletios A. ; Špička, Ivan ; Masszi, Tamás ; Hájek, Roman ; Rosiñol, Laura ; Goranova-Marinova, Vesselina ; Mihaylov, Georgi ; Maisnar, Vladimír ; Mateos, Maria-Victoria ; Wang, Michael ; Niesvizky, Ruben ; Oriol, Albert ; Jakubowiak, Andrzej ; Minarik, Jiri ; Palumbo, Antonio ; Bensinger, William ; Kukreti, Vishal ; Ben-Yehuda, Dina ; Stewart, A.Keith ; Obreja, Mihaela ; Moreau, Philippe

Blood, 2016-09, Vol.128 (9), p.1174-1180 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
2
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Usmani, Saad Z. ; Nahi, Hareth ; Mateos, Maria-Victoria ; van de Donk, Niels W.C.J. ; Chari, Ajai ; Kaufman, Jonathan L. ; Moreau, Philippe ; Oriol, Albert ; Plesner, Torben ; Benboubker, Lotfi ; Hellemans, Peter ; Masterson, Tara ; Clemens, Pamela L. ; Luo, Man ; Liu, Kevin ; San-Miguel, Jesus

Blood, 2019-08, Vol.134 (8), p.668-677 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
3
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

San-Miguel, Jesús ; Bladé, Joan ; Shpilberg, Ofer ; Grosicki, Sebastian ; Maloisel, Frédéric ; Min, Chang-Ki ; Polo Zarzuela, Marta ; Robak, Tadeusz ; Prasad, Sripada V.S.S. ; Tee Goh, Yeow ; Laubach, Jacob ; Spencer, Andrew ; Mateos, María-Victoria ; Palumbo, Antonio ; Puchalski, Tom ; Reddy, Manjula ; Uhlar, Clarissa ; Qin, Xiang ; van de Velde, Helgi ; Xie, Hong ; Orlowski, Robert Z.

Blood, 2014-06, Vol.123 (26), p.4136-4142 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.